Key Takeaways
- Guidance ex-GLP-1, upside optional: Management guided 12%–13% consolidated constant-currency growth for FY27, explicitly excluding any GLP-1 contribution, which remains a binary upside call tied to partner approvals.
- Cenexi turns the corner: The acquired European unit was EBITDA-positive for Q4 and three quarters of FY26, with a target to reach mid-to-high single-digit EBITDA margin by FY27-end and mid-teen margins in the medium term.
- GLP-1 capacity build is a 2030 story: Eight contracts are signed and six more are in the pipeline, but management sees the real ramp-up only after the 2030 U.S. patent expiry, with an insulin contract filling capacity in the interim.
- FY29 step-up flagged early: Management pointed to a couple of large, complex product launches in Q2 or Q3 FY29 that could push growth to 19%–20% or higher, setting a long-dated catalyst.
- What to watch next quarter: Whether the Saudi shipment freeze resolves, the pace of Cenexi’s margin climb toward the high-single-digit target, and any GLP-1 partner approval disclosures that would de-risk the ex-guidance upside.
Growth Drivers & Guidance
- FY27 build-up: Growth is expected from products launched last quarter annualizing, a multivitamin launching this quarter, 3–4 products contributing about $40 million, own new launches adding INR200 crores, base business contributing INR650 crores, and Cenexi adding INR150 crores, all excluding forex and GLP-1.
- FY28 trajectory: Management expects 15% growth, supported by settlement dates falling in FY28 for some products and the ramp-up of Cenexi’s new ampoule line installed in summer 2026.
- FY29 step-change: A couple of large, complex products are expected to launch in Q2 or Q3 FY29, which management flagged could lift growth to 19%–20% or more.
- CDMO momentum: The CDMO business grew 28% in FY26, with a major project progressing toward H2 FY28 commercialization at an annual revenue potential of USD2.5 cr to USD3 cr, and an additional INR4 cr to INR5 cr from CDMO contracts expected in FY27 base business.
- Dalbavancin launch: Approved in February and launched in the U.S. and Europe; the customer won a Vizient contract post-launch, and annualized sales are expected to be higher than Q4 levels.
- Middle East overhang: The ROW business dip was driven largely by no shipments to Saudi Arabia last quarter; management said shipments may resume next quarter if the situation cools down.
Srinivas Sadu: "FY '29 will be one big step up. A couple of complex products, which are big ones, will be launched probably third, second or third quarter FY '29. That could be one big step up."
Cenexi Turnaround
- Profitability inflection: Cenexi was EBITDA-positive in Q4 and for three quarters of FY26, driven by higher capacity utilization, contract renegotiations for inflation, workforce rationalization, and new product ramp-ups.
- FY27 margin target: Management aims for at least mid-single-digit to high-single-digit EBITDA margin by the end of FY27, with revenue touching approximately EUR20 cr; the improvement is expected to come more from efficiency than from a large revenue jump.
- Medium-term ambition: Mid-teen EBITDA margin is the stated objective, supported by deeper integration with Gland and cross-selling of Gland-developed products into Cenexi’s customer base.
- Capacity utilization: Fontenay is at nearly 100% utilization, with a new line being added and another being replaced to increase capacity; Osny’s solid orals line is at about 90%; the other two sites are at 50%–60%, with tech transfer programs and product launches underway.
- Cross-selling traction: Three marketing authorizations have been signed up for products developed by Gland to be manufactured at Cenexi sites; launches are possible from Q3 FY27 but mostly expected from FY28.
- New wins: Cenexi won a large contract with a leading European laboratory for a hormonal drug in prefilled syringes, and an existing customer asked to relaunch development of a solid product at the Osny site.
Srinivas Sadu: "The revenue increase may not be that great, probably, but mostly on the profitability, the improvement should be -- what you are seeing is more on the efficiency side."
GLP-1: The Ex-Guidance Upside
- Contract pipeline: Eight GLP-1 CDMO contracts have been signed, with an additional six to seven expected soon; all are for GLP-1 molecules.
- Guidance exclusion: Management explicitly excluded GLP-1 from its 12%–13% FY27 growth guidance, framing any GLP-1 revenue as upside contingent on partners securing approvals in different markets.
- Capacity timeline: The 14-crore-unit capacity build is aimed at the post-2030 opportunity when the U.S. patent expires; exhibit batches and filings are expected this year, with approvals possibly in Q3 FY27.
- Interim capacity fill: An insulin contract for vials and cartridges has been signed to occupy 3–4 crore units of capacity over the next couple of years, covering the majority of costs until the GLP-1 ramp-up begins.
- Disclosure constraints: Management declined to quantify contracted capacity, disclose which markets have received partner approvals, or provide volume guidance, citing partner confidentiality and the early stage of the ramp.
Srinivas Sadu: "We are not actually talking any numbers for GLP. Even the guidance we're giving is excluding GLP because it all depends on these partners getting approvals in different markets and volumes."
Margins & Cost Efficiency
- Full-year margin expansion: EBITDA margin improved 360 bps year-on-year, supported by the Cenexi turnaround, operating leverage from two additional lines commercialized, and cost efficiencies.
- Gross margin lift: Full-year gross margin rose 230 bps, driven by favorable product mix, operational efficiencies, and a higher contribution from value-added segments.
- Base business margin guide: Management guided base business EBITDA margin at 33%–35% for FY27, with consolidated EBITDA margin around 25%–26%.
- Cost optimization levers: Yield improvement, alternate sourcing, energy optimization, and process efficiencies contributed approximately 1% to 2% of margin improvement; additional actions include hedged power costs at Cenexi, a solar plant acquisition in India, and increasing batch sizes due to contract wins.
- Cash conversion: Working capital days improved to 164 from the prior year, driven by better inventory management and receivables control.
- Tax rate: Expected to improve as Cenexi profitability improves.
Ravi Mitra: "This will be sustainable in terms of long term."
U.S. & Base Business
- U.S. performance: Strong new product and volume-led growth, driven by new launches and increased volumes from existing and new GPO contracts; margins improved from operational efficiency and leverage.
- GPO contract wins: Several GPO contracts signed at the end of last year began selling from the beginning of this year, supported by a better cost structure; two more lines became operational this quarter, with one more line expected next quarter.
- Product engine: 31 products launched in the U.S. during FY26, including five in Q4; 24 ANDAs were filed and 28 approvals were received.
- Dalbavancin: Launched in February in the U.S. and European markets; the customer won a Vizient contract post-launch, and annualized numbers are expected to be higher than Q4 sales.
- Multivitamin: Approved in April and expected to be a meaningful contributor to growth in FY27 and beyond.
Strategic Investments & Capex
- Five-year capex plan: INR2,000 crores of capex announced over the next five years, with approximately INR500 crores planned for FY27.
- Ophthalmic line: Board approval received for an ophthalmic line with suspension capability, plus entry into blow-fill-seal technology; investment begins now.
- Cenexi capacity addition: A new high-capacity ampoule line will be installed in summer 2026 at Fontenay, adding 3 crore ampoules of capacity by 2027; the existing new ampoule filling line installed last year is ramping up as expected.
- AI and automation: Investments are being made across quality, R&D, and manufacturing to create structural efficiency advantages.
- CEO search: An active search is underway for a candidate with a stronger CDMO and biologics background.
- Cenexi strategic rationale: Management emphasized that the acquisition was not just for the existing business but to develop hormone products, explore controlled substances that cannot be manufactured in India, cross-sell Gland products into Cenexi’s customer base, and launch Gland’s own products from Cenexi sites.
Srinivas Sadu: "So there are multiple reasons why we acquired this, not just the business what they have. So as we speak, we have already started developing some hormone products. Now we're looking at the controlled substances, which you can't do in India, signing contracts with customers of Cenexi for our products and our own products getting launched in."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | 12%–13% constant-currency growth, excluding GLP-1 | FY27 |
| Consolidated EBITDA margin | Around 25%–26% | FY27 |
| Base business EBITDA margin | 33%–35% | FY27 |
| Cenexi EBITDA margin | Mid-to-high single digits | FY27-end |
| Cenexi revenue | Approximately EUR20 cr | FY27 |
| Cenexi medium-term EBITDA margin | Mid-teen | Medium term |
| Major CDMO project commercialization | Annual revenue potential USD2.5 cr–USD3 cr | H2 FY28 |
| FY28 consolidated growth | 15% | FY28 |
| FY29 growth step-up | 19%–20% or more, driven by complex product launches | Q2/Q3 FY29 |
| GLP-1 ramp-up | Full ramp-up post-U.S. patent expiry; insulin contract fills capacity in interim | Post-2030 |
| Capex | INR2,000 cr over five years; INR500 cr in FY27 | FY27–FY31 |
| Saudi Arabia shipments | May resume if geopolitical situation cools down | Next quarter |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹1,742.8 cr, +22% YoY |
| Full year FY26 consolidated revenue | ₹6,430.7 cr, +14.5% YoY |
| Adjusted EBITDA | ₹524.4 cr, margin 30%, +500 bps YoY |
| Full year FY26 adjusted EBITDA | ₹1,682.6 cr, margin 26%, +360 bps YoY |
| Adjusted PAT | ₹366.7 cr, margin 21% vs 13% in prior year |
| Full year FY26 adjusted PAT | ₹1,045.5 cr, margin 16% vs 12% in prior year |
| Consolidated gross margin | 66%, +30 bps YoY |
| Base business gross margin | 62%, +90 bps YoY |
| Base business adjusted EBITDA margin | 41% for Q4, 38% for full year FY26 |
| US revenue | ₹971.6 cr, +26% YoY; full year ₹3,318.1 cr, +11% |
| Europe and other regulated markets revenue | ₹79.4 cr; full year ₹324.9 cr, +11% |
| Rest of world revenue | ₹146.8 cr, +17% YoY; full year ₹651.1 cr, +7% |
| India revenue | ₹67 cr; full year ₹267.2 cr |
| Cenexi revenue | EUR4.5 cr, +4% YoY; full year EUR18.2 cr, +11% |
| Cenexi EBITDA | EUR0.1 cr, EBITDA positive |
| CDMO share of total revenue | 46%, +28% growth; base business CDMO at 23% of base revenue, +33% |
| R&D spend | ₹50.6 cr, ~4% of base business sales; full year ₹223 cr, 5% of base business revenue |
| US product launches in FY26 | 31 products launched, including 5 in Q4 |
| US ANDA filings and approvals in FY26 | 24 ANDAs filed, 28 approvals received |
| Cash and cash equivalents | ₹3,359.1 cr as of March 31, 2026 |
| Cash flow from operations | ₹404.5 cr for Q4; full year ₹1,031.4 cr vs ₹914.7 cr in FY25 |
| Cash conversion cycle | 164 days for FY26, improved YoY |
| Total capex FY26 | ₹493.8 cr |
| Effective tax rate | 28% for Q4; full year ~29% |
| GLP-1 cartridge capacity | 14 cr units; 8 contracts signed, 6–7 more expected |
| Cenexi external debt | ₹243.4 cr |
| Consolidated growth guidance FY27 | 12%–13% on constant currency, excluding GLP-1 |
| Consolidated CAGR target next four years | 15% |
| Cenexi midterm EBITDA target | Mid-teen EBITDA level |
| Base business EBITDA margin guidance | 33%–35%; consol EBITDA margin guided at 25%–26% |
| Capex outlay over next five years | ₹2,000 cr |
| FY27 expected capex | ~₹500 cr |
| Major CDMO project annual revenue potential | USD2.5 cr to USD3 cr, commercialization expected H2 FY28 |
| Cenexi FY27 revenue target | ~EUR20 cr |
| Other income | ₹111.5 cr for Q4; full year ₹316.3 cr |
| Profit share and milestone revenue mix | 9% profit share, 6% milestone |
| Cenexi Fontenay capacity utilization | ~100%; Osny solid orals ~90%; other two sites 50%–60% |
| Insulin capacity utilization on cartridge line | 3 cr to 4 cr units expected over next couple of years |